lead to losses of biological but not of immunological activities (Butt 1969) . The complete hormonal activity of the gonadotrophin can only be indicated by bioassays in vivo, but methods which depend upon binding to a receptor site will at least measure one facet of the biological activity, and such assays using testicular or ovarian receptors have been described (Catt et al. 1972 , Reichert & Bhalla 1974 . Alternatively those steroids produced in vitro under the influence of the gonadotrophin may be used as the end-point (Watson 1971 , Shirley & Stephenson 1973 . There is also the interesting approach of Rees et al. (1973) using a system for LH similar to that originally described for ACTH (Chayen et al. 1972) . The effect of LH on ascorbic acid in the luteinized ovary used in the assay of Parlow (1961) has been adapted to this in vitro technique. Reducing activity in the luteinized ovaries treated with LH is estimated by microdensitometry after staining with Prussian blue. Although this assay is tedious in comparison with radioimmunoassay it is even more sensitive and thus gives the possibility of measuring levels which are less than normal.
Dr R W Shaw (Department ofClinical Endocrinology, The Women's Hospital, Sparkhill, Birmingham, Bll 4HL)
(Estrogen Modulation of Gonadotrophin Release
CEstrogens play an important role in the control of the menstrual cycle in the human female. Although the understanding of cestrogen feedback circuits is far from complete, it appears that at different phases of the cycle aestrogens have different effects upon gonadotrophin release. During the early and mid-follicular phase, the increasing cestradiol levels suppress follicle stimulating hormone (FSH) and luteinizing hormone (LH) release. At midcycle, however, a positive release of gonadotrophins is seen in response to a higher but falling cestradiol level. These feedback effects are thought to be mediated via control of the secretion of hypothalamic gonadotrophin hormone-releasing hormone (LH-RH), as well as by direct action on the pituitary. To study the effects of cestrogen upon gonadotrophin release in vivo in the human female we have been using two approaches; first testing the pituitary's response to a standard dose of synthetic LH-RH in differing steroid environments, and second, testing the effects of injected cestrogens upon spontaneous LH and FSH release in various clinical states.
Effect of wstradiol upon pituitary responsiveness
to LH-RH: Throughout the normal menstrual cycle cestrogen levels change dramatically. The effects of synthetic LH-RH given at different stages during the cycle have previously been studied (Nillius & Wide 1972 , Thomas et al. 1972 , Yen et al. 1972 but in most instances the tests were not performed during the same cycle. Four normal women received 100 /.kg LH-RH intravenously on Days 4, 9, 14 and 22 of the same cycle. The LH response was always greater on Day 22 than on Days 4 or 9, but in each case the largest effect was seen on Day 14. The FSH responses showed no such differences throughout the cycle and certainly no marked increase at midcycle. The cestradiol levels on the various test days did not correlate with LH or FSH responses, although the highest cestradiol values were seen on Day 14, when the greatest LH response was observed (Shaw et al. 1974) .
To investigate whether alterations in cestradiol levels would bring about changes in response to LH-RH, normal women were treated with cestradiol benzoate in doses of 0.5 mg to 2.5 mg intramuscularly during the follicular phase of their cycles and the effects of LH-RH before and 48 hours after the aestrogen injection were measured.
Control subjects, receiving no oestrogen, showed no significant change in response, whereas those who received the cestradiol in most cases showed an increase in LH and FSH release. There was also a change in the rate of release, with the peak values of LH and FSH being delayed from 20-30 minutes in the controls to between 60 and 90 minutes in the cestrogen pretreated patients in 50 % of cases. A typical pattern is shown in Fig 1. No dose response relationship existed between the extent of the LH or FSH response and dose of injected cestrogen. Each subject appeared to have her own threshold, some were as equally well stimulated by 0.5 mg as others were by 2.5 mg cestradiol benzoate.
Effect of (Estradiol upon spontaneous gonadotrophin release: After the injection of 2.0 mg oestradiol benzoate intramuscularly to 6 normal women, peak levels of cestradiol were found between 8 and 24 hours, and levels had returned to near pre-injection levels by 56 to 72 hours. As with other previously reported studies (Tsai & Yen 1971 , Monroe et al. 1972 , Cargille et al. 1973 ) the cestrogen initially induced a fall in LH and FSH release, but by 36 to 48 hours the concentrations had returned to baseline and were then followed by a peak in LH release, occurring between 48 and 56 hours, reaching levels comparable to those seen during the mid-cycle ovulatory surge. Only 3 of the 6 had a rise in FSH concentrations.
This cestrogen test was then capable of inducing both negative and positive feedback stimuli in normal women. Marshall et al. (1973) have suggested that the failure of many patients to ovulate on clomiphene was due to an inability to respond to the positive cestrogen feedback at midcycle. We found that clomiphene responsiveness could be predicted by performing an cestrogen provocation test in order to test for positive feedback release of gonadotrophins. Fourteen patients with amenorrhoea of hypothalamic origin, were given 1 mg of aestradiol benzoate intramuscularly and LH and FSH levels measured 8 hourly over a 72-hour period. Two distinct groups of patients became apparent as shown in Fig 2 - patients capable of producing positive feedback release of LH, and those unable to do so. Six of the 14 subjects tested showed these positive feedback LH releases but only 3 showed accompanying FSH surges. All 6 subjects ovulated on clomiphene. Of the 8 subjects who were unable to produce positive feedback release of LH, none ovulated on clomiphene up to a dosage of 200 mg daily for 5 days. The aestrogen provocation test has therefore proved a useful mean of predicting clomiphene responsiveness in hypothalamic amenorrhoea (Shaw et al. 1975) .
The relative roles played by cestrogen, progesterone and 17-a hydroxyprogesterone in controlling the menstrual cycle are still undetermined. However, throughout the cycle changing aestrogen levels modulate LH and FSH secretion by means of negative and positive feedback circuits. Increased cestrogen levels appear to modify pituitary responsiveness to LH-RH. The ability to respond to positive feedback cestrogen stimulus is also of great importance in successfully inducing ovulation with clomiphene and the cestrogen provocation test may be useful in resolving the functional abnormality in hypothalamic amenorrhcea. 
Gonadotrophin Secretion in Androgen Disorders
The secretion of the gonadotrophins, follicle stimulating hormone (FSH) and luteinizing hormone (LH), by the pituitary gland controls sex hormone production in both male and female. Also spermatogenesis in the male and ovulation in the female are influenced by the gonadotrophins. The relationship between these pituitary hormones and gonadal function is complicated by the negative feedback control on the former. Thus a balance exists between these parts of the endocrine system as well as with the hypothalamus, the site of production and release of the gonadotrophin releasing hormone (LH-RH). Studies based on these interactions have been used to develop clinical tests of gonadal function as well as to elucidate the pathogenesis of reproductive disorders.
Disorders of the testes may present either as infertility or as failure of development of secondary sexual characteristics. The first of these arises from a defect in the seminiferous tubules, the second from a deficiency in the secretion of androgens by the Leydig cells. In either case the disease may be due to a primary gonadal disorder or be secondary to a failure of the secretion of gonadotrophins from the pituitary gland. This latter situation can occur as a result of an abnormality of the pituitary or in the production of the releasing hormone from the hypothalamus. In theory these alternatives can be resolved by measurement of gonadotrophin concentrations in the blood. Gonadotrophin levels will be elevated if severe enough disease originates in the testis whereas they will be low if there is primary involvement of the pituitary of hypothalamus. For example, FSH levels are usually high in patients with aspermia but normal in subjects with oligospermia (Van Thiel et al. 1972 , Isurugi et al. 1973 . There is indeed circumstantial evidence for the presence of a substance produced by the germinal epithelium in the course of sperm maturation which feeds back on to the pituitary to cause a suppression of FSH secretion (Van Thiel et al. 1972) . When there is deficient Leydig cell function with a consequent fall in the production of testosterone LH levels become raised, as publications based on radioimmunoassay methods confirm. Either FSH or LH levels are almost invariably elevated in this situation. Thus it is usually simple to diagnose testicular disease. It might be thought that the FSH and LH responses to LH-RH would be diagnostically useful on those rare occasions that the gonadotrophin measurements are unexpectedly normal along with a primary abnormality of the gonads. However, a review of the recent literature together with unpublished personal experience shows that in a combined series of 35 patients an exaggerated response to LH-RH was not found in any man in whom there was not already an elevation of basal FSH (Table 1) . Thus there is no indication for routinely performing LH-RH stimulation tests in males with suspected primary disorders of the testis. FSH measurement alone will usually suffice.
When the hypogonadism is considered to be due to gonadotrophin deficiency as evidenced by low or low normal concentrations of FSH and LH an LH-RH test may be useful. In this instance a normal rise in FSH and, more importantly, in LH levels after administration of the releasing hormone effectively excludes pituitary disease (Marshall et al. 1972 ). However, failure to respond in a short-term test carried out within two hours of giving a single dose of LH-RH does not allow a choice to be made between deficient hypothalamic or pituitary function. Such a distinction must await the definition of normal criteria following the prolonged administration of the hypothalamic hormone.
Thus a diagnostic plan for employing gonadotrophin measurements in the elucidation of the underlying pathology in cases of male hypogonadism involves first the basal measurement of FSH levels. Only if these are low or in the lower part of the normal range is there any advantage in proceeding to an LH-RH test.
Whereas the diagnostic problems in the adult male relate to the underproduction of androgens, the reverse is true of the female. In women pathological amounts of androgen may be secreted by the ovaries or adrenal glands. It is well known that there is a relationship in the female between the secretion of gonadotrophins and gonadal steroids, such as cestrogens and progesterone, analogous to that in the male, but relatively little attention has been paid to the role of androgens in the control of gonadotrophin secretion in women. There is however an inverse relationship between basal serum testosterone levels and LH concentrations in women suffering from poly-
